Since a combination of ER and HER2 therapy is clinically-used for the treatment of patients with ER+/HER2+ breast cancer, we also applied an ER inhibitor fulvestrant and a HER2 inhibitor lapatinib to the preclinical studies of in vitro cell viability assays. This evidence concerns the gene ERBB2 and breast carcinoma.